克里奥医疗集团(Creo Medical Group)在H1 2025年使收入翻了一番,并削减了损失,而EMV Capital则获得了命运制药公司用于发展的抗生素资产。 Creo Medical Group doubled revenue and cut losses in H1 2025, while EMV Capital acquired Destiny Pharma’s antibiotic assets for development.

Creo Medical Group 报告了强劲的 2025 年上半年业绩，收入增长 40% 至 220 万英镑，基本经营亏损减少 43%，这得益于成本削减和欧洲业务的重大出售。 Creo Medical Group reported strong first-half 2025 results with a 40% revenue increase to £2.2 million and a 43% reduction in underlying operating losses, aided by cost cuts and a major sale of its European business. 尽管每股季度损失4英镑,但该公司将现金储备增加到2 050万英镑,并重申了全年收入增长40-60%的预测。 Despite a quarterly loss of GBX 4 per share, the company boosted cash reserves to £20.5 million and reaffirmed its full-year revenue growth forecast of 40–60%. 埃姆维资本以高达2475万英的价格收购了Destiny Pharma的抗生素资产,包括XF-73鼻凝平台,并计划推进第三阶段试验并获得美国批准. EMV Capital acquired Destiny Pharma’s antibiotic assets, including the XF-73 nasal gel platform, for up to £2.475 million, with plans to advance phase III trials and pursue U.S. approval.